Ligand Pharmaceuticals Incorporated

Healthcare · Biotechnology

Overall research band Weak

Quality Very weak

Valuation Very weak

Balance sheet Very weak

Market confirmation Strong

One-minute company read

What this report can tell you now

What the company does

Ligand Pharmaceuticals Incorporated is a biopharmaceutical company based in Emeryville, California, focused on sourcing and advancing technologies to support pharmaceutical companies worldwide in discovering and developing new therapeutic solutions. Its portfolio includes commercialized products for hematologic malignancies such as Kyprolis and Evomela for multiple myeloma, and Rylaze for acute lymphoblastic leukemia and lymphoblastic lymphoma. In infectious diseases, Ligand offers Veklury for COVID-19, Vaxneuvance for Streptococcus pneumoniae, and Pneumosil for pediatric pneumonia. The company also provides bone health treatments like Teriparatide injection and Duavee, as well as other products including Zulresso for postpartum depression, Nexterone, Noxafil-IV, and the Aziyo portfolio for pericardial repair. Ligand's customers include pharmaceutical companies and healthcare providers, and its revenue model is based on commercializing its own products, supplying proprietary Captisol materials, and collaborating with partners on clinical development programs.

The current research profile is Mixed Setup, with elevated leverage. This is a starting point for investigation, not a forecast or recommendation.

Strongest visible signal

Recent market behavior is the strongest visible confirmation. Check whether it agrees with the underlying business evidence.

What to investigate next

Read the latest filing or company update, check the period behind the metrics, and investigate the dimension with the weakest band above.

Before you draw a conclusion

Read the latest filing or company update.
Check the financial period behind each metric.
Investigate the weakest score band and any missing evidence.

Headline fundamentals

A small set of signals worth checking

ROIC3.6%Model input; read with the evidence status and period context.

Operating margin17.6%Model input; read with the evidence status and period context.

Revenue CAGR · 4 years2.6%Model input; read with the evidence status and period context.

FCF margin18.2%Model input; read with the evidence status and period context.

Go deeper when you need to

Compare the right companies, understand what changed, and monitor the evidence.

Peer contextCompare companies using the appropriate economic neighborhood.

Evidence detailSee exact inputs, source context, and model-aware metrics.

HistoryReview score and research changes over time.

MonitoringKeep the questions, risks, and changes that matter in view.

The public report remains useful on its own. Premium adds depth, history, comparison, and monitoring.